HB-200
Phase 1Small molecule
HB-200 is one of 17 small molecule programs targeting Papilloma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Papilloma
#DrugCompanyPhaseTrials
1Vistide
GileadApproved
Celebrex
PPhiladelphia Eye Associates
Approved
HPV Vaccine
SShanghai Zerun Biotechnology Co.,Ltd
Phase 3
Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Recombinant Human GM-CSF
EEastern Cooperative Oncology Group
Phase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 2
Paraplatin
AAvyxa
Phase 2
Gardasil9
Merck & Co.Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HB-200. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details